Levoglucosan (LG, LEV, Leucoglucosan, Glucosan, 1,6-anhydro-b-D-Glucose) is an endogenous metabolite.
research use only
Cat.No.S3319
|
In vitro |
DMSO
: 32 mg/mL
(197.36 mM)
Water : 32 mg/mL Ethanol : 32 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 162.14 | Formula | C6H10O5 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 498-07-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | LG, LEV, Leucoglucosan, Glucosan, 1,6-anhydro-b-D-Glucose | Smiles | OC1C(O)C2COC(O2)C1O | ||
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06404632 | Recruiting | Life Style|Health-Related Behavior|Disabilities Mental|Disability Physical|Acceptability of Health Care |
Region Stockholm|Karolinska Institutet|Promobilia Foundation |
April 12 2024 | Not Applicable |
| NCT06372301 | Recruiting | Transthyretin Amyloid Cardiomyopathy|Aortic Stenosis |
Steen Hvitfeldt Poulsen|Aarhus University Hospital Skejby |
April 2 2024 | Not Applicable |
| NCT04941599 | Recruiting | Familial Hypercholesterolemia |
Vanderbilt University Medical Center|National Heart Lung and Blood Institute (NHLBI) |
February 14 2024 | Phase 2 |
| NCT06130787 | Recruiting | LeukemiaMyeloid Chronic |
University Hospital Clermont-Ferrand |
November 17 2023 | Not Applicable |
| NCT06040164 | Not yet recruiting | PreDiabetes|Diabetes Mellitus Type 2|Obesity|Oral Dysbiosis|Mouth Disease |
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud |
October 1 2023 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.